Survodutide is a dual-acting medication that targets both the glucagon and GLP-1 receptors. This gives it the benefits of typical GLP-1s—like lowering appetite and improving blood sugar—while also activating glucagon pathways that help boost energy burn and reduce liver fat. Early research indicates it may be a breakthrough not only for weight loss, but also for treating metabolic dysfunction–associated steatohepatitis (MASH), more commonly known as fatty liver disease.